| ［1］ Yendamuri S, Caty L, Pine M, et al. Outcomes of sarcomatoid carcinoma of the lung: a surveillance, epidemiology, and end results database analysis［J］. Surgery, 2012, 152(3): 397-402. DOI: 10.1016/j.surg.2012.05.007.
［2］ Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification［J］. J Thorac Oncol, 2015, 10(9): 1243-1260. DOI: 10.1097/JTO.0000000000000630.
［3］ Pelosi G, Melotti F, Cavazza A, et al. A modified vimentin histological score helps recognize pulmonary sarcomatoid carcinoma in small biopsy samples［J］. Anticancer Res, 2012, 32(4): 1463-1473.
［4］ Ung M, Rouquette I, Filleron T, et al. Characteristics and clinical outcomes of sarcomatoid carcinoma of the lung［J］. Clin Lung Cancer, 2016, 17(5): 391-397. DOI: 10.1016/j.cllc.2016.03.001.
［5］ Gu L, Xu Y, Chen Z, et al. Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma［J］. Biomed Pharmacother, 2015, 76: 134-140. DOI: 10.1016/j.biopha.2015.10.009.
［6］ Roesel C, Terjung S, Weinreich G, et al. Sarcomatoid carcinoma of the lung: a rare histological subtype of nonsmall cell lung cancer with a poor prognosis even at earlier tumour stages［J］. Interact Cardiovasc Thorac Surg, 2017, 24(3): 407413. DOI: 10.1093/icvts/ivw392.
［7］ Vieira T, Girard N, Ung M, et al. Efficacy of firstline chemotherapy in patients with advanced lung sarcomatoid carcinoma［J］. J Thorac Oncol, 2013, 8(12): 1574-1577. DOI: 10.1097/01.JTO.0000437008.00554.90.
［8］ Chang YL, Wu CT, Shih JY, et al. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy［J］. Ann Surg Oncol, 2011, 18(10): 2952-2960. DOI: 10.1245/s10434-011-1621-7.
［9］ Lococo F, Gandolfi G, Rossi G, et al. Deep sequencing analysis reveals that KRAS mutation is a marker of poor prognosis in patients with pulmonary sarcomatoid carcinoma［J］. J Thorac Oncol, 2016, 11(8): 1282-1292. DOI: 10.1016/j.jtho.2016.04.020.
［10］ Kim S, Kim MY, Koh J, et al. Programmed death1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas［J］. Eur J Cancer, 2015, 51(17): 2698-2707. DOI: 10.1016/j.ejca.2015.08.013.
［11］ Vieira T, Antoine M, Hamard C, et al. Sarcomatoid lung carcinomas show high levels of programmed death ligand1 (PDL1) and strong immunecell infiltration by TCD3 cells and macrophages［J］. Lung Cancer, 2016, 98: 51-58. DOI: 10.1016/j.lungcan.2016.05.013.
［12］ Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1［J］. Gene, 2018, 654: 77-86. DOI: 10.1016/j.gene.2018.02.026.
［13］ Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria［J］. J Clin Oncol, 2007, 25(13): 1753-1759. DOI: 10.1200/JCO.2006.07.3049. |
